Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Hiltbrunner S, Britschgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P, Weder W, Opitz I, Lauk O, Caviezel C, Bachmann H, Tabor A, Schröder P, Knuth A, Münz C, Stahel R, Boyman O, Renner C, Petrausch U, Curioni-Fontecedro A.
Hiltbrunner S, et al. Among authors: bachmann h.
Ann Oncol. 2021 Jan;32(1):120-121. doi: 10.1016/j.annonc.2020.10.474. Epub 2020 Oct 21.
Ann Oncol. 2021.
PMID: 33098996
Free article.
Clinical Trial.
No abstract available.